Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List
Market access improves with approximately 5 million people in the Texas Medicaid patient network SOLANA BEACH, Calif. , April 19, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,
View HTML
Toggle Summary Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape
SOLANA BEACH, Calif. , March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that together with the research team at H.C. Wainwright & Co.
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3  Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare professionals SOLANA BEACH, Calif. , March 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML
Toggle Summary Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
SOLANA BEACH, Calif. , March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2021 financial results
View HTML
Toggle Summary Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022
Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology study SOLANA BEACH , Calif., and CHICAGO , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
View HTML
Toggle Summary GIMOTI® Commercialization Update
New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com   Expanded Coverage with recent New York Medicaid Approval SOLANA BEACH, Calif. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma ,
View HTML
Toggle Summary Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
SOLANA BEACH, Calif. and CHICAGO , Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Services, LLC , an independent provider of global commercial
View HTML
Toggle Summary Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
SOLANA BEACH, Calif. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases, today announced that the Company will participate in the H.C.
View HTML
Toggle Summary Evoke Pharma Reports Third Quarter 2021 Financial Results
SOLANA BEACH, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the quarter ended September 30, 2021 and recent corporate
View HTML
Toggle Summary Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021
SOLANA BEACH, Calif. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its third quarter 2021 financial results on
View HTML